CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total sales are derived from generics and off-patent branded drugs. Generic drugs ...

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

SOPA Images / Contributor / Getty Images Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders.

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...